Mazdutide Shows Significant Weight Loss in Phase 3 Trial
Key Summary Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity. 84.3%
Read MoreKey Summary Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity. 84.3%
Read MoreIn the recent Nutrients study, researchers looked examined the links between cardiometabolic risk (CMR) variables (Cardiometabolic Health) and legume intake.
Read More